Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $27.50.
Several analysts recently weighed in on the company. Piper Sandler started coverage on Kestra Medical Technologies in a report on Monday, March 31st. They issued an "overweight" rating and a $27.00 price objective for the company. Wolfe Research assumed coverage on Kestra Medical Technologies in a research report on Monday, March 31st. They set an "outperform" rating and a $29.00 price target on the stock. Bank of America began coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They set a "buy" rating and a $30.00 target price for the company. Wells Fargo & Company initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They issued an "overweight" rating and a $28.00 price target on the stock. Finally, Stifel Nicolaus began coverage on shares of Kestra Medical Technologies in a report on Monday, March 31st. They issued a "buy" rating and a $28.00 price target for the company.
Read Our Latest Stock Report on KMTS
Institutional Trading of Kestra Medical Technologies
Hedge funds and other institutional investors have recently made changes to their positions in the business. Yu Fan bought a new stake in shares of Kestra Medical Technologies during the 1st quarter worth $56,880,000. T. Rowe Price Investment Management Inc. acquired a new position in shares of Kestra Medical Technologies in the 1st quarter valued at $56,613,000. Omega Fund Management LLC purchased a new position in Kestra Medical Technologies in the 1st quarter worth about $44,754,000. Alliancebernstein L.P. acquired a new stake in Kestra Medical Technologies during the 1st quarter worth about $29,500,000. Finally, Brown Advisory Inc. purchased a new stake in Kestra Medical Technologies during the first quarter valued at about $13,716,000.
Kestra Medical Technologies Trading Down 1.4%
Shares of Kestra Medical Technologies stock traded down $0.22 on Wednesday, hitting $15.19. 273,100 shares of the company's stock traded hands, compared to its average volume of 451,876. Kestra Medical Technologies has a 52-week low of $14.08 and a 52-week high of $26.15. The business's 50-day simple moving average is $19.71.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings data on Monday, April 14th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same period in the prior year, the business earned ($1.18) EPS.
About Kestra Medical Technologies
(
Get Free ReportWe are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
See Also

Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.